Abstract
The purpose of this study was to elicit relative preferences for common treatment options of relapsed follicular lymphoma, and their associated attributes, amongst lymphoma patients in Alberta, and lymphoma-treating physicians in Canada, using a discrete choice experiment (DCE). Treatment administration, toxicity, survival free of relapse and cost were the attributes evaluated for four treatment options: standard chemotherapy (CT), radioimmunotherapy (RIT), high-dose CT and auto-SCT, and allo-SCT. For the 81 patients and 48 physicians who participated in this study, survival free of relapse was a positive influence on choice (P<0.001), whereas negative influences on choice included toxicity of allo-SCT (P<0.001 for patients, P=0.005 for physicians) and cost (P=0.001 for physicians only). The estimated uptake of the treatment options for patients was as follows: auto-SCT (69%), RIT (14%), CT (11%) and allo-SCT (7%). The distribution for physicians was similar (56, 20, 19 and 4%, respectively). In conclusion, patients with relapsed follicular lymphoma are able to consider the different attributes of various treatment options and are willing to trade off the need for hospitalization, associated toxicity and cost associated with autologous transplantation in order to benefit from an increased PFS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780–2795.
Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontel C et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 1587–1594.
Horning SJ . Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88.
Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475.
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne R et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301.
Crawley CR, Foran JM, Gupta RK, Rohatnier AZS, Summers K, Matthews J et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol 2000; 11: 861–865.
Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071.
Keating MJ, McLaughlin P, Cabanillas F . Low-grade non-Hodgkin's lymphoma–development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care (Engl) 1997; 6: 21–26.
Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629–636.
Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431.
Wiseman GA, Witzig TE . Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185–188.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463.
Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554–2559.
Schouten HC, Qian W, Kvaloy S, Porcellini A, Hogberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.
van Besien K, Loberiza Jr FR, Bajorunaite R, Armitage JO, Bashey A, Burns L et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.
Ryan M . Discrete choice experiments in health care. BMJ 2004; 328: 360–361.
Ryan M, Gerard K . Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2: 55–64.
Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5: 1–186.
Lancsar E, Louviere J . Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 2008; 26: 661–677.
Hensher DA, Rose JM, Greene WH . Applied Choice Analysis: a Primer. Cambridge University Press: Cambridge, 2005.
Lancsar E, Louviere J . Deleting ‘irrational’ responses from discrete choice experiments: a case of investigating or imposing preferences? Health Econ 2006; 15: 797–811.
Caldon LJ, Walters SJ, Ratcliffe J, Reed MW . What influences clinicians’ operative preferences for women with breast cancer? An application of the discrete choice experiment. Eur J Cancer 2007; 43: 1662–1669.
Salkeld G, Solomon M, Butow P, Short L . Discrete-choice experiment to measure patient preferences for the surgical management of colorectal cancer. Br J Surg 2005; 92: 742–747.
Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M . Patients’ preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 2004; 328: 382.
Cairns J, van der Pol M, Lloyd AJ . Decision making heuristics and the elicitation of preferences: being fast and frugal about the future. Health Econ 2002; 11: 655–658.
Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13: 956–964.
Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21: 2324–2331.
Tarella C, Ladetto M, Benedetti F, Vitolo U, Pulsoni A, Patti C et al. A recent update of three consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma (FL) shows a sizeable group of patients surviving in continuous complete remission up to 16 years after the end of treatment: should we still consider FL an incurable disease? Blood 2009; 114: 363 (abstract 882).
Acknowledgements
The project was funded by an unrestricted research grant from Glaxo-Smith-Kline, Canada.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Shafey, M., Lupichuk, S., Do, T. et al. Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant 46, 962–969 (2011). https://doi.org/10.1038/bmt.2010.225
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.225
Keywords
This article is cited by
-
Differences between physician and patient preferences for cancer treatments: a systematic review
BMC Cancer (2023)
-
Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
BMC Cancer (2021)
-
Risk as an Attribute in Discrete Choice Experiments: A Systematic Review of the Literature
The Patient - Patient-Centered Outcomes Research (2014)
-
Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making?
Applied Health Economics and Health Policy (2013)
-
Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma
Bone Marrow Transplantation (2012)